Sinco Pharmaceuticals Holdings Ltd. (HK:6833)
:6833
Top Page
Sinco Pharmaceuticals Holdings Ltd.
(6833)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$0.18
▲(0.56% Upside)
Action:ReiteratedDate:09/24/25
The overall stock score of 60 reflects solid revenue growth and a stable balance sheet, offset by challenges in cash flow management and a bearish technical outlook. The valuation suggests potential undervaluation, but liquidity concerns and lack of momentum weigh on the score.
Positive Factors
Diversified revenue model & R&D focus
Sinco's business combines R&D, manufacturing and multi-channel sales to hospitals, pharmacies and partners, plus government contracts. That diversified model reduces customer concentration and supports steady product uptake, enabling durable revenue streams and sustained investment in innovation.
Negative Factors
Recent revenue contraction
A near-term revenue decline of ~16.5% reflects weakening top-line momentum that, if persistent, can impair long-term R&D funding, commercial investments and market share. Sustained revenue contraction would pressure margins and limit the company's ability to execute strategic growth initiatives over 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue model & R&D focus
Sinco's business combines R&D, manufacturing and multi-channel sales to hospitals, pharmacies and partners, plus government contracts. That diversified model reduces customer concentration and supports steady product uptake, enabling durable revenue streams and sustained investment in innovation.
Read all positive factors
Sinco Pharmaceuticals Holdings Ltd. (6833) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$376.08M
Dividend Yield1.12%
Average Volume (3M)210.00K
Price to Earnings (P/E)9.5
Beta (1Y)0.24
Revenue Growth-16.52%
EPS Growth-8.87%
CountryHK
Employees291
SectorHealthcare
Sector Strength45
IndustryAdvertising Agencies
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,032,890,600
10 Day Avg. Volume85,200
30 Day Avg. Volume210,000
Financial Highlights & Ratios
PEG Ratio-19.24
Price to Book (P/B)0.59
Price to Sales (P/S)0.14
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinco Pharmaceuticals Holdings Ltd. Business Overview & Revenue Model
Company Description
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin...
How the Company Makes Money
Sinco Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include both proprietary medications and generic drugs. The company's revenue model is diversified, with key revenue streams stemming from dir...
Sinco Pharmaceuticals Holdings Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.49B | 2.82B | 2.54B | 2.27B | 2.02B | 2.05B |
| Gross Profit | 257.43M | 299.94M | 323.28M | 305.87M | 364.95M | 273.83M |
| EBITDA | 117.26M | 132.60M | 126.01M | 109.01M | 197.69M | 152.05M |
| Net Income | 42.56M | 42.05M | 42.35M | 69.46M | 135.08M | 118.14M |
Balance Sheet | ||||||
| Total Assets | 1.88B | 2.00B | 1.89B | 1.42B | 1.23B | 1.25B |
| Cash, Cash Equivalents and Short-Term Investments | 232.63M | 308.32M | 437.92M | 329.14M | 326.05M | 143.76M |
| Total Debt | 227.90M | 350.54M | 251.40M | 192.41M | 340.95M | 82.13M |
| Total Liabilities | 1.20B | 1.34B | 1.26B | 820.52M | 857.88M | 1.09B |
| Stockholders Equity | 683.60M | 662.88M | 628.05M | 603.81M | 374.89M | 165.34M |
Cash Flow | ||||||
| Free Cash Flow | -4.48M | -268.05M | 289.16M | 22.39M | 282.19M | 136.93M |
| Operating Cash Flow | 21.86M | -232.88M | 353.70M | 75.08M | 305.71M | 137.30M |
| Investing Cash Flow | -44.48M | -52.87M | -63.63M | -119.27M | -22.73M | -46.84M |
| Financing Cash Flow | -19.05M | 154.59M | -189.73M | 35.04M | -97.11M | -169.88M |
Sinco Pharmaceuticals Holdings Ltd. Technical Analysis
Negative
0.18
Price Trends
0.18
Positive
0.18
Negative
0.20
Negative
Market Momentum
<0.01
Negative
48.99
Neutral
63.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6833, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.18, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.99 is Neutral, neither overbought nor oversold. The STOCH value of 63.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6833.
Sinco Pharmaceuticals Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$376.08M | 9.52 | 5.03% | 1.12% | -16.52% | -8.87% | |
59 Neutral | HK$2.85B | -10.50 | -17.49% | ― | 10.61% | -1448.48% | |
57 Neutral | HK$3.31B | 19.79 | 4.13% | ― | 35.73% | -88.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$850.83M | -104.06 | -5.88% | ― | -4.13% | 76.38% | |
39 Underperform | HK$310.80M | -21.81 | ― | ― | -38.24% | -31.99% |
* Healthcare Sector Average
HK:6833
Sinco Pharmaceuticals Holdings Ltd.
0.19
0.02
13.50%
HK:1762
Wanka Online, Inc.
1.69
1.14
207.27%
HK:1993
Asiaray Media Group Ltd.
0.65
-0.13
-16.67%
HK:0205
SEEC Media Group Limited
0.68
0.56
466.67%
HK:2131
Netjoy Holdings Limited
0.46
0.00
0.00%
HK:2422
Rego Interactive Co., Ltd.
1.73
1.37
380.56%
Sinco Pharmaceuticals Holdings Ltd. Corporate Events
Sinco Pharmaceuticals Enhances Internal Controls Following Listing Rule Breach
Dec 5, 2025
Sinco Pharmaceuticals Holdings Limited has announced the results of its internal control remediation following an interest-free loan granted to Mr. Huang Xiangbin, which breached the Listing Rules. The company has taken corrective actions by revis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.